Live
Pfizer is hailing its experimental drug for treating COVID as a “gamechanger” after it was found to cut rates of hospitalisation or death by nearly 90 per cent in vulnerable patientsOn average, stringency o.
The drug company is so confident it has stopped trials early and is pursuing approvals while governments are also getting their orders in quick, with the USA securing millions of dosesEssential retailers.
The results appear to surpass those seen with Merck & Co’s pill molnupiravirThe territory., which was shown last month to halve the likelihood of dying or being hospitalised for COVID-19 patients also at high risk of serious illnessThe photographic records o.
LINK
Copyright © 2011 JIN SHI